Skip to main content
Fig. 4 | Breast Cancer Research

Fig. 4

From: Phase I clinical trial of the combination of eribulin and everolimus in patients with metastatic triple-negative breast cancer

Fig. 4

NanoString PanCancer Pathways® analysis (n = 20). a Volcano plot showing differentially expressed genes with linear fold change > 2 and p < 0.05 comparing SD+PD and PR. b Decreased CDKN2A expression (p = 0.02) in responders. c Increased CALML5 expression (p = 0.01) in responders

Back to article page

Breast Cancer Research

ISSN: 1465-542X

Contact us